Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
10-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
8-K/A - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2025. Eric Hines, Chief Executive Officer of Milestone Scientific commented: "When I joined Milestone in August 2025, we were in the middle of the third quarter following a period without consistent execut
ROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced that it will host a conference call at 8:30 AM Eastern Time on Wednesday, April 1, 2026, to discuss the company's financial results for the fourth quarter and full year ended December 31, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 875878. A webcast and replay of the
ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates. The program, which commenced on February 1, 2026, targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor (MAC) jurisdictions, including Novitas, First Coast, Noridian,
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
ROSELAND, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dawood Sayed, M.D., a nationally recognized leader in interventional pain medicine, to its Board of Directors, effective immediately. Dr. Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center and currently serves as Division Chief of Pain Medicine, Director of Interventional Spine Services, and Director of the Center for Neuromodulation. With a robust clinical, academic, and policy background, he brings over a deca
ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor
ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief Executive Officer, effective immediately. Mr. Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including healthcare. Most recently, he served as President of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada, and Latin America and increased annual revenue from approximately $50 m
Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2025. Eric Hines, Chief Executive Officer of Milestone Scientific commented: "When I joined Milestone in August 2025, we were in the middle of the third quarter following a period without consistent execut
ROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced that it will host a conference call at 8:30 AM Eastern Time on Wednesday, April 1, 2026, to discuss the company's financial results for the fourth quarter and full year ended December 31, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 875878. A webcast and replay of the
ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company's transformation and growth initiatives. Eric Hines, Chief Executive Officer of Milestone Scientific, stated, "During the third quarter, we made measurable progress executing our plan to build a leaner, more focused organization capable of sustained growth and improved profitability. Through disciplined cost management and operati